The company posted a net profit of $157 million, or $1.29 per share, down from $193 million in the same period last year. On an adjusted basis, earnings reached $1.39 per share, falling short of the $1.43 consensus estimate from analysts polled by FactSet. While total sales dipped 1% to $1.67 billion, the figure marginally surpassed Wall Street’s revenue forecast of $1.64 billion.

Management attributed the sluggish performance to a difficult start to the quarter, citing the impact of the government shutdown and a pivot by consumers toward lower-cost alternatives. However, Clorox noted that consumption trends began to stabilize in late December and showed continued improvement through January.

Volume Declines Hit Core Household Segments

Performance across the portfolio was uneven, as the company navigated both supply chain transitions and changing retail habits. According to the report, growth in specialized sectors was offset by volume declines in high-volume categories:

• Lifestyle and household product sales dropped by 5% and 6%, respectively, on lower consumption.
• Health and wellness revenue rose 2%, bolstered by shipments related to a U.S. ERP software transition.
• International sales grew 7%, supported by favorable pricing and currency exchange rates.

Looking ahead, Clorox reaffirmed its guidance for fiscal year 2026. The company expects adjusted earnings to land between $5.95 and $6.30 per share, even as it projects a net sales decline of 6% to 10%. This cautious outlook suggests that while volume trends may be recovering, the path to sustained growth remains constrained by volatile market conditions.